Oslo, October 8, 2021: Ultimovacs ASA today announced two senior appointments to
its management team: Orla Mc Callion as Head of Regulatory Affairs & QA and Anne
Worsøe as Head of Investor Relations & Communication, both effective October
1, 2021.


As Head of Regulatory Affairs & QA, Orla Mc Callion will manage the strategic
planning and implementation of regulatory procedures across all Ultimovacs'
development products. Orla brings a wealth of industry knowledge with more than
20 years of experience in the pharmaceutical industry, and is an accomplished
scientist and leader within regulatory and clinical development. Orla has
regularly interacted with EMA, FDA and other national Regulatory Authorities for
scientific advice procedures, submissions for serious conditions, orphan
designations and pediatric-related activities and to secure clinical trial
approvals. Previously, Orla was Director of Regulatory Affairs at OxThera AB.
Orla holds a Ph.D. in Pharmacy from Queen's University in Belfast.

Orla commented: "I am delighted to join the Ultimovacs team at this exciting
time and hope to support the company's growth as an innovative and leading
oncology company."


As Head of Investor Relations & Communication Anne Worsøe will oversee the
communication between Ultimovacs' management, investors and the broader public.
With 20 years of experience within the investment industry, she has extensive
knowledge in strategy and business development, internationalization, PR,
branding & communication. Anne was the first CEO of the Norwegian Venture
Capital & Private Equity Association and Venture Partner at Antler, a global
venture capital firm. She spent four years in the USA as Director of Innovation
Norway in San Francisco. Anne has served on the Boards of several early-stage
companies, venture capital funds, private and public limited companies, and
served as an expert jury member at the European Commission's EIC Accelerator
program. Anne holds a Master of Business and Economics from Norwegian Business
School.

Anne  commented:  "I  am  honored  to  join  Ultimovacs  and  to  work  with  an
extraordinary  team of visionary scientists and  industry leaders, making a real
impact  for cancer patients. I am genuinely enthusiastic about the journey ahead
for the company. "

"Ultimovacs can attract highly talented people across many disciplines and
geographies, and we are very excited to welcome Orla and Anne to our team. Both
bring substantial expertise to Ultimovacs at a time when the company is being
increasingly recognized as a global leader in therapeutic cancer vaccines," says
CEO Carlos de Sousa.

About Ultimovacs:

Ultimovacs' mission is to and extend and improve the life of patients by
enabling the immune system to fight cancer. The Company is developing immune-
stimulatory vaccines to treat a broad range of cancers. Ultimovacs' lead
universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present
in over 80% of cancers in all stages of tumor growth. By directing the immune
system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate
an immune system cascade and increase anti-tumor responses. With a broad Phase
II program, Ultimovacs aims to clinically demonstrate UV1's impact in multiple
cancer types in combination with other immunotherapies. Ultimovacs' second
technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET)
platform, combines tumor-specific peptides and adjuvant in the same molecule and
entered Phase I studies in 2021.

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com (mailto:carlos.desousa@ultimovacs.com)
Phone: +47 908 92507

Anne Worsøe, Head of IR & Communication
Email: anne.worsoe@ultimovacs.com (mailto:anne.worsoe@ultimovacs.com)
Phone: +47 906 86815